Recommendations for cancer screening are uncertain for the early detection or prevention of prostate cancer in African American men. Thus, chemoprevention strategies are needed to specifically target African American men.
Methods
The evidence was examined on the biological etiology of disparities in African Americans related to prostate cancer. Possible chemopreventive agents and biomarkers critical to prostate cancer in African American men were also studied.
Results
High-grade prostatic intraepithelial neoplasia may be more prevalent in African American men, even after controlling for age, prostate-specific antigen (PSA) level, abnormal results on digital rectal examination, and prostate volume. Prostate cancer in African American men can lead to the overexpression of signaling receptors that may mediate increased proliferation, angiogenesis, and decreased apoptosis. Use of chemopreventive agents may be useful for select populations of men.
Conclusions
Green tea catechins are able to target multiple pathways to address the underlying biology of prostate carcinogenesis in African American men, so they may be ideal as a chemoprevention agent in these men diagnosed with high-grade prostatic intraepithelial neoplasia.
MakridakisN.M., ReichardtJ.K.Molecular epidemiology of hormone-metabolic loci in prostate cancer.Epidemiol Rev.2001; 23(1): 24–29.
4.
ChornokurG., DaltonK., BorysovaM.E.Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer.Prostate.2011; 71(9): 985–997.
5.
PowellI.J.Epidemiology and pathophysiology of prostate cancer in African-American men.J Urol.2007; 177(2): 444–449.
6.
IlicD., O'ConnorD., GreenS.Screening for prostate cancer: an updated Cochrane systematic review.BJU Int.2011; 107(6): 882–891.
7.
MoyerVAUS Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med.2012; 157(2): 120–134.
8.
AndrioleG.L., CrawfordE.D., GrubbR.L.3rd. Mortality results from a randomized prostate-cancer screening trial.N Engl J Med.2009; 360(13): 1310–1319.
9.
LippmanS.M., HongW.K.Cancer prevention science and practice.Cancer Res.2002; 62(18): 5119–5125.
10.
MontironiR., MazzucchelliR., Lopez-BeltranA.Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate.Nat Clin Pract Urol.2007; 4(6): 321–332.
11.
SuzukiH., UedaT., IchikawaT.Androgen receptor involvement in the progression of prostate cancer.Endocr Relat Cancer.2003; 10(2): 209–216.
12.
ZlottaA.R., EgawaS., PushkarD.Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men.J Natl Cancer Inst.2013; 105(14): 1050–1058.
13.
WoltersT., RoobolM.J., SteyerbergE.W.The effect of study arm on prostate cancer treatment in the large screening trial ERSPC.Int J Cancer.2010; 126(10): 2387–2393.
14.
CunninghamG.R., AshtonC.M., AnnegersJ.F.Familial aggregation of prostate cancer in African-Americans and white Americans.Prostate.2003; 56(4): 256–262.
15.
GibbsM., StanfordJ.L., JarvikG.P.A genomic scan of families with prostate cancer identifies multiple regions of interest.Am J Hum Genet.2000; 67(1): 100–109.
16.
Kote-JaraiZ., OlamaA.A., GilesG.G.Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.Nat Genet.2011; 43(8): 785–791.
17.
EelesR.A., OlamaA.A., BenllochS.Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.Nat Genet.2013; 45(4): 385–391, 391e1-391e2.
18.
FreedmanM.L., MonteiroA.N., GaytherS.A.Principles for the post-GWAS functional characterization of cancer risk loci.Nat Genet.2011; 43(6): 513–518.
19.
HaimanC.A., PattersonN., FreedmanM.L.Multiple regions within 8q24 independently affect risk for prostate cancer.Nat Genet.2007; 39(5): 638–644.
20.
StevensV.L., AhnJ., SunJ.HNF1B and JAZF1 genes, diabetes, and prostate cancer risk.Prostate.2010; 70(6): 601–607.
21.
ShenM.M., Abate-ShenC.Molecular genetics of prostate cancer: new prospects for old challenges.Genes Dev.2010; 24(18): 1967–2000.
22.
StegemanS., AmankwahE., KleinK.A large-scale analysis of genetic variants within putative miRNA binding sites in prostate cancer.Cancer Discov.2015; 5(4): 368–379.
23.
ChornokurG., AmankwahE.K., DavisS.N.Variation in HNF1B and obesity may influence prostate cancer risk in African American men: a pilot study.Prostate Cancer.2013; 2013: 384594.
24.
EelesR.A., Kote-JaraiZ., GilesG.G.Multiple newly identified loci associated with prostate cancer susceptibility.Nat Genet.2008; 40(3): 316–321.
25.
GudmundssonJ., SulemP., SteinthorsdottirV.Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.Nat Genet.2007; 39(8): 977–983.
BinghamC., HattersleyA.T.Renal cysts and diabetes syndrome resulting from mutations in hepatocyte nuclear factor-1β.Nephrol Dial Transplant.2004; 19: 2703–2708.
28.
HaldorsenI.S., VesterhusM., RaederH.Lack of pancreatic body and tail in HNF1B mutation carriers.Diabet Med.2008; 25(7): 782–787.
29.
NakayamaK., NozuY., GotoY.HNF1B alterations associated with congenital anomalies of the kidney and urinary tract.Pediatr Nephrol.2010; 25(6): 1073–1079.
30.
CornelisM.C., AgrawalA., ColeJ.W.The Gene, Environment Association Studies consortium (GENEVA): maximizing the knowledge obtained from GWAS by collaboration across studies of multiple conditions.Genet Epidemiol.2010; 34(4): 364–372.
31.
HanK.S., JeongI.G., JoungJ.Y.Prevalence of high-grade prostatic intraepithelial neoplasia in prostate gland of Korean men: comparisons between radical prostatectomy and cystoprostatectomy.Urology.2007; 70(6): 1100–1103.
32.
PaliwalS., KoviR.C., NathB.The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor.Cancer Res.2007; 67(19): 9322–9329.
33.
ThomasG., JacobsK.B., YeagerM.Multiple loci identified in a genome-wide association study of prostate cancer.Nat Genet.2008; 40(3): 310–315.
34.
LindquistK.J., ParisP.L., HoffmannT.J.Mutational landscape of aggressive prostate tumors in African American men.Cancer Res.2016; 76(7): 1860–1868.
35.
YatsulaB., GalvaoC., McCrannM.Assessment of F-MuLV-induced tumorigenesis reveals new candidate tumor genes including Pecam1, St7, and Prim2.Leukemia.2006; 20(1): 162–165.
36.
BergerM.F., LawrenceM.S., DemichelisF.The genomic complexity of priary human prostate cancer.Nature.2011; 470: 214–220.
37.
BacaS.C., PrandiD., LawrenceM.S.Punctuated evolution of prostate cancer genomes.Cell.2013; 153(3): 666–677.
38.
AlexandrovL.B., Nik-ZainalS., WedgeD.C.Signatures of mutational processes in human cancer.Nature.2013; 500(7463): 415–421.
CooperC.S., EelesR., WedgeD.C.Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.Nat Genet.2015; 47(4): 367–372.
41.
ClarkJ., MersonS., JhavarS.Diversity of TMPRSS2-ERG fusion transcripts in the human prostate.Oncogene.2007; 26(18): 2667–2673.
MosqueraJ.M., MehraR., ReganM.M.Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.Clin Cancer Res.2009; 15(14): 4706–4711.
44.
TiguertR., GheilerE.L., TefilliM.V.Racial differences and prognostic significance of tumor location in radical prostatectomy specimens.Prostate.1998; 37(4): 230–235.
45.
TiguertR., GheilerE.L., TefilliM.V.Racial differences and prognostic significance of tumor location in radical prostatectomy specimens.Prostate.199837(4): 230–235.
46.
FeibusA.H., LevyJ., McCaslinI.R.Racial variation in prostate needle biopsy templates directed anterior to the peripheral zone.Urol Oncol.2016; 34(8): 336.e1-6.
47.
FaisalF.A., SundiD., TosoianJ.J.Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location.Eur Urol.2016; 70(1): 14–17.
48.
EpsteinJ.I., HerawiM.Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care.J Urol.2006; 175(3 pt 1): 820–834.
49.
KelloffG.J., LiebermanR., SteeleV.E.Chemoprevention of prostate cancer: concepts and strategies.Eur Urol.1999; 35(5-6): 342–350.
50.
LiebermanR.Prostate cancer chemoprevention: strategies for designing efficient clinical trials.Urology.2001; 57(4 suppl 1): 224–229.
51.
FowlerJ.E.Jr, BiglerS.A., LynchC.Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race.Cancer.2001; 91(7): 1291–1296.
52.
PowellI.J., BockC.H., RuterbuschJ.J.Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.J Urol.2010; 183(5): 1792–1796.
53.
PottsJ.M., LutzM., WalkerE.Trends in PSA, age and prostate cancer detection among black and white men from 1990-2006 at a tertiary care center.Cancer.2010; 116(16): 3910–3915.
54.
TsivianM., BanezL.L., KetoC.J.African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center.Prostate Cancer Prostatic Dis.2013; 16(1): 91–94.
55.
ChornokurG., HanG., TannerR.High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: results from a pilot study.Cancer Lett.2013; 331(2): 154–157.
56.
TanP.H., TanH.W., TanY.Is high-grade prostatic intraepithelial neoplasia on needle biopsy different in an Asian population: a clinicopathologic study performed in Singapore.Urology.2006; 68(4): 800–803.
57.
MartinB.J., FinlayJ.A., SterlingK.Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA).Prostate Cancer Prostatic Dis.2004; 7(2): 132–137.
58.
LiljaH., UlmertD., VickersA.J.Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.Nat Rev Cancer.2008; 8(4): 268–278.
59.
GeeJ., BaileyH., KimK.Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1alpha-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.Prostate.2013; 73(9): 970–978.
60.
KryvenkoO.N., BaliseR., Soodana PrakashN.African-American men with Gleason score 3+3=6 prostate cancer produce less prostate specific antigen than Caucasian men: a potential impact on active surveillance.J Urol.2016; 195(2): 301–306.
61.
PeskoeS.B., JoshuC.E., RohrmannS.Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer.Prostate.2015; 75(11): 1167–1176.
62.
HerawiM., KahaneH., CavalloC.Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled.J Urol.2006; 175(1): 121–124.
63.
TanejaS.S., MortonR., BarnetteG.Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.J Clin Oncol.2013; 31(5): 523–529.
64.
KumarN.B., Pow-SangJ., EganK.M.Randomized, placebo-controlled trial of green tea catechins for prostate cancer prevention.Cancer Prev Res (Phila).2015; 8(10): 879–887.
65.
AminM.M., JeyaganthS., FahmyN.Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation.Can Urol Assoc J.2007; 1(3): 245–249.
66.
BryantR.J., LiljaH.Emerging PSA-based tests to improve screening.Urol Clin North Am.2014; 41(2): 267–276.
67.
D'AmicoA.V., WhittingtonR., MalkowiczS.B.Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.JAMA.1998; 280(11): 969–974.
68.
ShuchB., MikhailM., SatagopanJ.Racial disparity of epidermal growth factor receptor expression in prostate cancer.J Clin Oncol.2004; 22(23): 4725–4729.
69.
GastonK.E., KimD., SinghS.Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer.J Urol.2003; 170(3): 990–993.
70.
deVere WhiteR.W., DeitchA.D., JacksonA.G.Racial differences in clinically localized prostate cancers of black and white men.J Urol.1998; 159(6): 1979–1982.
71.
GuoY., SigmanD.B., BorkowskiA.Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-American patients.Prostate.2000; 42(2): 130–136.
72.
KimH.S., MoreiraD.M., JayachandranJ.Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men.Prostate Cancer Prostatic Dis.2011; 14(3): 262–265.
73.
WallaceT.A., PrueittR.L., YiM.Tumor immunobiological differences in prostate cancer between African-American and European-American men.Cancer Res.2008; 68(3): 927–936.
74.
YangG., AddaiJ., IttmannM.Elevated caveolin-1 levels in African-American versus white-American prostate cancer.Clin Cancer Res.2000; 6(9): 3430–3433.
75.
ReamsR.R., AgrawalD., DavisM.B.Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.Infect Agent Cancer.2009; 4(suppl 1): S3.
76.
ChienJ., StaubJ., AvulaR.Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer.Oncogene.2005; 24(32): 5089–5100.
77.
KelloffG.J., LippmanS.M., DannenbergA.J.Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer–a plan to move forward.Clin Cancer Res.2006; 12(12): 3661–3697.
78.
AndrioleG.L., BostwickD., BrawleyO.W.The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.J Urol.2011; 185(1): 126–131.
79.
HamiltonR.J., KahwatiL.C., KinsingerL.S.Knowledge and use of finasteride for the prevention of prostate cancer.Cancer Epidemiol Biomarkers Prev.2010; 19(9): 2164–2171.
80.
ThompsonI.M., GoodmanP.J., TangenC.M.The influence of finasteride on the development of prostate cancer.N Engl J Med.2003; 349(3): 215–224.
81.
AggarwalB.B., PrasadS., ReuterS.Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: “reverse pharmacology” and “bedside to bench” approach.Curr Drug Targets.2011; 12(11): 1595–1653.
82.
AminA.R., KucukO., KhuriF.R.Perspectives for cancer prevention with natural compounds.J Clin Oncol.2009; 27(16): 2712–2725.
83.
AravindaramK., YangN.S.Anti-inflammatory plant natural products for cancer therapy.Planta Med.2010; 76(11): 1103–1117.
84.
GogtayN.J., BhattH.A., DalviS.S.The use and safety of non-allopathic Indian medicines.Drug Saf.2002; 25(14): 1005–1019.
85.
JiaL.Cancer complementary and alternative medicine research at the US National Cancer Institute.Chin J Integr Med.2012; 18(5): 325–332.
86.
KannappanR., GuptaS.C., KimJ.H.Tocotrienols fight cancer by targeting multiple cell signaling pathways.Genes Nutr.2012; 7(1): 43–52.
87.
ReddyB.S.Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues.Prev Med.1996; 25(1): 48–50.
88.
WargovichM.J., JimenezA., McKeeK.Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression.Carcinogenesis.2000; 21(6): 1149–1155.
89.
MinichD.M., BlandJ.S.A review of the clinical efficacy and safety of cruciferous vegetable phytochemicals.Nutr Rev.2007; 65(6 pt 1): 259–267.
90.
ScottE.N., GescherA.J., StewardW.P.Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials.Cancer Prev Res (Phila).2009; 2(6): 525–530.
91.
LippmanS.M., KleinE.A., GoodmanP.J.Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).JAMA.2009; 301(1): 39–51.
92.
KumarN., CrockerT., SmithT.Prostate cancer chemoprevention targeting men with high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP): model for trial design and outcome measures.J Clin Trials.2012; 2(1).
93.
KumarN., CrockerT., SmithT.Prostate cancer chemoprevention targeting high risk populations: model for trial design and outcome measures.J Cancer Sci Ther.2012; 2011(S3).
94.
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group.N Engl J Med.1994; 330(15): 1029–1035.
95.
OmennG.S., GoodmanG.E., ThornquistM.D.Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial.J Natl Cancer Inst.1996; 88(21): 1550–1559.
96.
KakaralaM., BrennerD.E., KorkayaH.Targeting breast stem cells with the cancer preventive compounds curcumin and piperine.Breast Cancer Res Treat.2010; 122(3): 777–785.
97.
ParnesH.L., BrawleyO.W., MinasianL.M.Phase III prostate cancer chemoprevention trials.Recent Results Cancer Res.2014; 202: 73–77.
98.
BettuzziS., BrausiM., RizziF.Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.Cancer Res.2006; 66(2): 1234–1240.
99.
HarperC.E., PatelB.B., WangJ.Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.Prostate.2007; 67(14): 1576–1589.
100.
McLartyJ., BigelowR.L., SmithM.Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro.Cancer Prev Res (Phila).2009; 2(7): 673–682.
101.
KumarN.B., Pow-SangJ., EganK.M.Effect of polyphenon E on progression to prostate cancer after diagnosis of high grade prostatic intraepithelial neoplasia or atypical small acinar proliferation in African American men. Presented at: American Association for Cancer Research; November 9–12, 2014; San Antonio, Texas.
102.
AlbrechtD.S., ClubbsE.A., FerruzziM.Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation.Chem Biol Interact.2008; 171(1): 89–95.
103.
PaschkaA.G., ButlerR., YoungC.Y.Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate.Cancer Lett.1998; 130(1-2): 1–7.
104.
YuH.N., YinJ.J., ShenS.R.Growth inhibition of prostate cancer cells by epigallocatechin gallate in the presence of Cu2+.J Agric Food Chem.2004; 52(3): 462–466.
105.
McCarthyS., CaporaliA., EnkemannS.Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer.Mol Oncol.2007; 1(2): 196–204.
106.
NyskaA., SuttieA., BakshiS.Slowing tumorigenic progression in TRAMP mice and prostatic carcinoma cell lines using natural anti-oxidant from spinach, NAO–a comparative study of three anti-oxidants.Toxicol Pathol.2003; 31(1): 39–51.
107.
SartorL., PezzatoE., DonaM.Prostate carcinoma and green tea: (-)epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model.Int J Cancer.2004; 112(5): 823–829.
108.
RahmaniA.H., Al ShabrmiF.M., AllemailemK.S.Implications of Green Tea and Its Constituents in the Prevention of Cancer via the Modulation of Cell Signalling Pathway.Biomed Res Int.2015; 2015: 925640.
109.
ChuuC.P., ChenR.Y., KokontisJ.M.Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.Cancer Lett.2009; 275(1): 86–92.
110.
KaoY.H., HiipakkaR.A., LiaoS.Modulation of endocrine systems and food intake by green tea epigallocatechin gallate.Endocrinology.2000; 141(3): 980–987.
111.
RenF., ZhangS., MitchellS.H.Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells.Oncogene.2000; 19(15): 1924–1932.
112.
HastakK., GuptaS., AhmadN.Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells.Oncogene.2003; 22(31): 4851–4859.
113.
SiddiquiI.A., AdhamiV.M., AfaqF.Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinasepathways by tea polyphenols in human prostate cancer cells.J Cell Biochem.2004; 91(2): 232–242.
114.
SiddiquiI.A., MalikA., AdhamiV.M.Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.Oncogene.2008; 27(14): 2055–2063.
115.
KleinerD.E., Stetler-StevensonW.G.Matrix metalloproteinases and metastasis.Cancer Chemother Pharmacol.1999; 43 Suppl: S42–51.
116.
NandakumarV., VaidM., KatiyarS.K.(-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells.Carcinogenesis.2011; 32(4): 537–544.
117.
AdhamiV.M., AhmadN., MukhtarH.Molecular targets for green tea in prostate cancer prevention.J Nutr.2003; 133(7 suppl): 2417S–2424S.
118.
ConnorsS.K., ChornokurG., KumarN.B.New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer.Nutr Cancer.2012; 64(1): 4–22.
119.
KaziA., DanielK.G., SmithD.M.Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosisinducing ability of genistein.Biochem Pharmacol.2003; 66(6): 965–976.
120.
NamS., SmithD.M., DouQ.P.Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo.J Biol Chem.2001; 276(16): 13322–13330.
121.
SmithD.M., WangZ., KaziA.Synthetic analogs of green tea polyphenols as proteasome inhibitors.Mol Med.2002; 8(7): 382–392.
122.
AdhamiV.M., SiddiquiI.A., SarfarazS.Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease.Clin Cancer Res.2009; 15(6): 1947–1953.
123.
CaporaliA., DavalliP., AstancolleS.The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.Carcinogenesis.2004; 25(11): 2217–2224.
124.
GuptaS., HastakK., AhmadN.Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols.Proc Natl Acad Sci U S A.2001; 98(18): 10350–10355.
125.
KhanN., AdhamiV.M., MukhtarH.Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies.Nutr Cancer.2009; 61(6): 836–841.
126.
KimS.J., AmankwahE., ConnorsS.Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice.Cancer Prev Res (Phila).2014; 7(4): 435–444.
127.
SiddiquiI.A., ZamanN., AzizM.H.Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas.Carcinogenesis.2006; 27(4): 833–839.
128.
SuttieA., NyskaA., HasemanJ.K.A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model.Toxicol Pathol.2003; 31(1): 31–38.
129.
YangC.S., LambertJ.D., HouZ.Molecular targets for the cancer preventive activity of tea polyphenols.Mol Carcinog.2006; 45(6): 431–435.
130.
BrausiM., RizziF., BettuzziS.Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update.Eur Urol.2008; 54(2): 472–473.
131.
ChowH.H., CaiY., AlbertsD.S.Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E.Cancer Epidemiol Biomarkers Prev.2001; 10(1): 53–58.
132.
ChowH.H., CaiY., HakimI.A.Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals.Clin Cancer Res.2003; 9(9): 3312–3319.
133.
ChowH.H., HakimI.A., ViningD.R.Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals.Clin Cancer Res.2005; 11(12): 4627–4633.
134.
JatoiA., EllisonN., BurchP.A.A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma.Cancer.2003; 97(6): 1442–1446.
135.
NguyenM.M., AhmannF.R., NagleR.B.Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities.Cancer Prev Res (Phila).2012; 5(2): 290–298.
136.
PistersK.M., NewmanR.A., ColdmanB.Phase I trial of oral green tea extract in adult patients with solid tumors.J Clin Oncol.2001; 19(6): 1830–1838.
137.
KumarN.B., Pow-SangJ., SpiessPE. Effect of polyphenol E on progression to prostate cancer after diagnosis of high grade prostatic intraepithelial neoplasia or atypical small acinar proliferation in African American men: preliminary finds of a phase II randomized, double-blind, placebo-controlled clinical trial. Presented at: 7th Annual American Association of Cancer Research Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; November 9, 2015; San Antonio, TX.
138.
EskewL.A., BareR.L., McCulloughD.L.Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate.J Urol.1997; 157(1): 199–202.
